In July 2021, the Executive Committee of the Stop TB Partnership approved US$6.14 million for Wave 9 funding to be awarded to 11 projects, in 8 countries, focusing on innovative approaches to address drug resistant tuberculosis (DR-TB) with support from the United States Agency for International Development (USAID) and Global Affairs Canada

UZT was among recipients of this grant that will support scale-up of newer and shorter all-oral regimens for Drug resistant TB (DR-TB), through introduction of Xpert® MTB/XDR assay for detection of second-line drug resistance


For UZT, the TB Reach support will be for 2 years.

  • Project Title: Optimizing SHORRT in Zimbabwe
  • Project Goal: To treat all people with DR-TB
  • Objectives
    1. To provide DST for FQ to at least 90% of patients detected with MDR/RR-TB
    2. To enroll at least 183 (100%) detected DR-TB patients on treatment
    3. To enroll at least 165 (90%) DR-TB patients on an all oral regimen
    4. To ensure a treatment success rate of at least 80% among DR-TB patients initiating treatment

Project Setting

The project will be implemented in Bulawayo, Midlands and Matabeleland South provinces, which contribute two thirds of national case load for DR-TB.

In 2023, with TB REACH support:

Community Leaders Sensitised
Community Health Workers Sensitised
Healthcare Workers Trained